- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01945580
Xenform Postmarket Surveillance Study (Xenform)
A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective is to evaluate clinical effectiveness of transvaginal repair with Xenform against traditional native tissue repair in women surgically treated for anterior and/or apical pelvic organ prolapse. Secondary objectives are to evaluate Xenform-related complications and subject reported outcomes.
The primary endpoint of the study is to achieve non-inferiority of transvaginal repair with Xenform over native tissue repair at 36 months as compared to baseline. Success will be based on a composite of objective and subjective measures.
Additionally, a co-primary endpoint of the study is to achieve non-inferiority of transvaginal repair with Xenform to native tissue repair for safety by comparing rates of serious device or serious procedure related complications between baseline and the 36 month time point.
The secondary endpoints of the study include assessments of complications and subject reported outcomes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- University of California, Irvine Medical Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory Hospital
-
Augusta, Georgia, United States, 30912
- Augusta University
-
Canton, Georgia, United States, 30114
- Cherokee Womens Health Specialist
-
-
Illinois
-
Skokie, Illinois, United States, 60076
- Northshore University Health System
-
-
Louisiana
-
Crowley, Louisiana, United States, 70526
- Acadia Women's Health
-
-
Maryland
-
Hanover, Maryland, United States, 21061
- Chesapeake Urology Research Associates
-
Owings Mills, Maryland, United States, 21117
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Cambridge, Massachusetts, United States, 02138
- Mount Auburn Hospital
-
-
Michigan
-
Kalamazoo, Michigan, United States, 49009
- Beyer Research
-
-
New Jersey
-
Voorhees, New Jersey, United States, 08043
- Cooper University Hospital
-
-
New York
-
Buffalo, New York, United States, 14222
- University of Buffalo
-
New York, New York, United States, 10003
- Beth Israel Medical Center
-
New York, New York, United States, 10016
- NYU Langone Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
Gastonia, North Carolina, United States, 28054
- Carolina Urology Partners
-
Winston-Salem, North Carolina, United States, 27103
- Lyndhurst Clinical Research
-
-
Ohio
-
Dresden, Ohio, United States, 43821
- Prime Care of SEO
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Prisma Health System
-
West Columbia, South Carolina, United States, 29169
- Southern Urogynecology
-
-
Tennessee
-
Franklin, Tennessee, United States, 37067
- Center for Pelvic Health
-
-
Texas
-
Dallas, Texas, United States, 75230
- Practice Research Organization
-
Houston, Texas, United States, 77030
- Houston Metro Urology
-
Irving, Texas, United States, 75062
- Las Colinas ObGyn
-
-
Washington
-
Covington, Washington, United States, 98042
- MultiCare Women's Health Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is female
- Subject is at least 18 years of age
- Subject has pelvic organ prolapse with the leading edge at or beyond the hymen. At or beyond the hymen is defined as POP-Q scores of Ba≥0 (for prolapse of the anterior compartment alone) or C≥0 (for prolapse of the apical compartment alone) or C≥-1/2 TVL and Ba≥0 (for a multi-compartment prolapse that includes the anterior and apical compartments).
- Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3, response of 2 or higher (i.e., responses of "somewhat", "moderately", or "quite a bit")
- Subject or subject's legally authorized representative is willing to provide written informed consent
- Subject is willing and able to comply with the follow-up regimen
Exclusion Criteria:
- Subject is pregnant or intends to become pregnant during the study
- Subject has an active or chronic systemic infection including any gynecologic infection, untreated urinary tract infection (UTI) or tissue necrosis
- Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder, colo-rectal or cervical)
- Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area
- Subject has taken systemic steroids (within the last month), or immunosuppressive or immunomodulatory treatment (within the last 3 months)
- Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus erythematosus (SLE), Marfan syndrome, Ehlers Danlos, collagenosis, polymyositis, polymyalgia rheumatica)
- Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis
- Subject has uncontrolled diabetes mellitus (DM)
- Subject has a known neurologic or medical condition affecting bladder function (e.g., multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)
- Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse (colpocleisis)
- Subject is not able to conform to the modified dorsal lithotomy position
- Subject is currently participating in or plans to participate in another device or drug study during this study
- Subject has a known sensitivity to any Xenform component
- Subject has had previous prolapse repair with mesh in the target compartment
- Subject is planning to undergo a concomitant prolapse repair with use of mesh in the non-target compartment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Xenform
Prolapse Repair with Xenform Soft Tissue Repair Matrix
|
Transvaginal anterior/apical pelvic organ prolapse repair
Other Names:
|
Active Comparator: Control
Prolapse Repair with Native Tissue Only
|
Transvaginal anterior/apical pelvic organ prolapse repair
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Success at 36 Months
Time Frame: 36 Months
|
The primary endpoint of the study was to achieve non-inferiority of transvaginal repair with Xenform over NTR at 36 months as compared to baseline. Success was based on a composite of objective and subjective measures.
|
36 Months
|
Number of Participants With One or More Serious Device-related and/or Procedure-Related Adverse Events
Time Frame: 36 months
|
Co-primary endpoint of the study was to achieve non-inferiority of transvaginal mesh repair with Xenform to NTR for safety by comparing rates of serious device-related or serious procedure-related complications between baseline and the 36-month time point.
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Mesh Erosion
Time Frame: 36 months
|
Incidence of Mesh Erosion at 36 months
|
36 months
|
Number of Participants With Mesh Exposure
Time Frame: 36 Months
|
Incidence of mesh exposure at 36 months
|
36 Months
|
Number of Participants With de Novo Dyspareunia
Time Frame: 36 months
|
Incidence of de novo dyspareunia at 36 months
|
36 months
|
Subject Specific Outcomes Measured With the Pelvic Floor Impact Questionnaire (PFIQ-7)]
Time Frame: 36 months
|
Improvement in subject specific outcomes at 36 months compared to baseline [quality of life (QOL) per the Pelvic Floor Impact Questionnaire (PFIQ-7)] The PFIQ-7 is composed of three separate but related assessments: the UIQ-7 addresses the impact of urinary incontinence symptoms, the CRAIQ-7 addresses the impact of colorectal-anal or bowel symptoms, and the POPIQ-7 addresses impact of vaginal and pelvic symptoms. For each question, the low score (0) corresponds to "not at all" and the high score (3) corresponds to "quite a bit". The scores for the UIQ-7, CRAIQ-7 and POPIQ-7 are additive to yield the final PFIQ-7 score. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life. Reported score is change from baseline at 36 months. |
36 months
|
Subject Specific Outcomes Measured by the Pelvic Floor Symptoms Per the Pelvic Floor Distress Inventory (PFDI-20)
Time Frame: 36 months
|
Improvement in subject specific outcomes at 36 months compared to baseline [pelvic floor symptoms per the Pelvic Floor Distress Inventory (PFDI-20)] The Pelvic Floor Distress Inventory-20 (PFDI-20) is complimentary to the PFIQ-7 and focuses on symptoms of distress in the same compartmentalized fashion as the PFIQ-7. Like the PFIQ-7, the PFDI-20 consists of three components: Urinary Distress Inventory (UDI; 6 questions), the Pelvic Organ Prolapse Distress Inventory (POPDI; 6 questions), and Colorectal-Anal Distress Inventory (CRADI; 8 questions). The scoring for the PFDI-20 is similar to the PFIQ-7 where each individual component score is summed. The total ranges from 0 to 300 with a higher score indicating a greater impact to QOL (i.e., distress symptoms are more noticeable) and a lower score indicating a lesser impact to QOL (i.e., distress symptoms are less noticeable). The reported result is change from baseline at 36 months. |
36 months
|
Subject Specific Outcomes Measured by the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)
Time Frame: 36 months
|
Improvement in subject specific outcomes at 36 months compared to baseline [change in sexual functioning per the Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)] This is a self-administered questionnaire and the responses are graded on a five-point Likert scale ranging from 0 (always) to 4 (never). Values range from 0 to 48 and a higher score indicates better sexual function. The reported result is change from baseline at 36 months. |
36 months
|
Subject Specific Outcomes: Pain Measured by the TOMUS Pain Scale
Time Frame: 36 months
|
Improvement in subject specific outcomes at 36 months compared to baseline [pain per the TOMUS pain scale] The TOMUS Pain Score, a visual analog instrument with a scale of 0 (no pain sensation) to 10 (most intense pain sensation imaginable), was used to assess pain associated with surgery for pelvic organ prolapse in this study. There are seven (7) questions each with a maximum score of 10 and a possible score range of 0-70). The reported results are change from baseline at 36 months. |
36 months
|
Subject Improvement Measured by the Patient Global Impression of Improvement for Prolapse (PGI-I)
Time Frame: 36 months
|
Assessment of subject's level of improvement, measured by the Patient Global Impression of Improvement for Prolapse (PGI-I) The Patient Global Impression of Improvement (PGI-I) for prolapse symptoms is a validated QOL instrument that assesses patient perception of overall improvement after surgical interventions for POP.12 The scale rates the patient's improvement or worsening of prolapse symptoms relative to baseline. The scale is as follows: 1- Very much better; 2- Much better; 3- A little better; 4- No change; 5- A little worse; 6- Much worse; 7- Very much worse. Assessments were performed at 6-month intervals beginning 6 months after the index procedure. |
36 months
|
Number of Participants With Re-Intervention or Re-Surgery
Time Frame: 36 months
|
Absence of re-intervention or re-surgery for recurrence or persistence of POP or Xenform exposure/erosion
|
36 months
|
Surgical Success
Time Frame: 36 months
|
Surgical success based on the following composite outcome:
|
36 months
|
Incidence of Complications
Time Frame: 36 Months
|
Incidence of the following device-related or procedure-related adverse events (AEs): pelvic pain, infection, vaginal shortening, atypical vaginal discharge, neuromuscular problems, vaginal scarring, de novo vaginal bleeding, fistula formation and/or de novo voiding dysfunction.
|
36 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peter Rosenblatt, MD, Mount Auburn Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- U9920
- AUGS PFD Outcome Registry (Registry Identifier: AUGS PFD Outcome Registry)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Organ Prolapse
-
University of CalgaryAlberta Health services; Cook Group IncorporatedCompletedAnterior Pelvic Organ ProlapseCanada
-
Coloplast A/SCompletedPelvic Organ Prolapse (POP)United States
-
University of British ColumbiaCompletedPelvic Organ Prolapse, Patient EducationCanada
-
University of MelbourneCompletedVaginal Hysterectomy | Pelvic Organ Prolapse Vaginal SurgeryAustralia
-
Unity Health TorontoUnknownVoiding Dysfunction After Pelvic Organ Prolapse SurgeryCanada
-
Nykøbing Falster County HospitalZealand University Hospital; University Hospital, Gentofte, Copenhagen; Copenhagen...UnknownBenign Hysterectomy | Postoperative Pelvic Organ Prolapse | Suspension
-
Mackay Medical CollegeRecruitingPelvic Organ Prolapse | Stage III and IV High Grade Pelvic Organ ProlapseTaiwan
-
Peking Union Medical College HospitalUnknown
-
Gaziosmanpasa Research and Education HospitalRecruitingPatients With Pelvic Organ Prolapse | Pectopexy | Lateral Suspension | Pop-q | Pisq-12Turkey
-
Charles University, Czech RepublicUnknownPelvic Organ Prolapse RecurrenceCzech Republic
Clinical Trials on Prolapse Repair
-
Kaiser PermanenteCompletedUrinary Incontinence | Cystocele | Uterine ProlapseUnited States
-
University of Sao PauloUniversity of Sao Paulo General Hospital; Federal University of São Paulo; Irmandade... and other collaboratorsUnknown
-
Kenneth Peters, MDWilliam Beaumont HospitalsCompleted
-
Ullevaal University HospitalCompletedPelvic Organ Prolapse | Urinary Stress Incontinence
-
Groupe Hospitalier de la Rochelle Ré AunisColoplast A/SCompleted
-
Coloplast A/STerminated
-
University Of PerugiaCompletedUrinary Incontinence | Pelvic Organ ProlapseItaly
-
University of CalgaryAlberta Health services; Cook Group IncorporatedCompletedAnterior Pelvic Organ ProlapseCanada
-
PromedonRecruiting
-
Medical University of ViennaNot yet recruitingPelvic Organ Prolapse